Toronto, Ontario–(Newsfile Corp. – July 31, 2020) – Psyched Wellness Ltd. (formerly, Duncan Park Holdings Corporation) (OTC Pink: DCNPF) (the “Company“) wishes to announce in connection with its press release dated June 1st, 2020, the Company has completed a third and final tranche of a non-brokered private placement for gross proceeds of $187,595 through the issuance of 1,875,595 common shares (each, a “Common Share“) at a price of $0.10 per Common Share (the “Offering“).
The proceeds of the Offering will be used to develop the Company’s business and for general working capital purposes.
The Common Shares issued in connection with the Offering are subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation.
The Company has made an application to list its Common Shares on the Canadian Securities Exchange but at this time it is not possible to confirm if or when such listing will occur. The Company will provide further updates with respect to the potential listing as they become available.
For further information, please contact:
Chief Executive Officer
Psyched Wellness Ltd.
This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control.
Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”.
By identifying such information and statements in this manner, the Company is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, the Company has made certain assumptions. Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward- looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice.
[NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/60907
Benchmark Provides Update on Financial Condition of Potanicals
Vancouver, British Columbia–(Newsfile Corp. – October 23, 2020) – Benchmark Botanics, Inc. (CSE: BBT) (“Benchmark” or the “Company”) Benchmark announces that the ongoing working capital deficiency of Potanicals Green Growers Inc. (“Potanicals“), the Company’s wholly owned subsidiary, may result in Potanicals being unable to meet all of its accounts payable at October 31, 2020, including its October 31, 2020 payroll obligations for all 39 of Potanicals’ employees, which will cause material uncertainty about Potanicals’ ability to continue as a going concern. During the period from January 1, 2019 to December 31, 2019, Potanicals had a net loss of approximately $1,736,000. As at October 22, 2020, Potanicals had cash of $102,493, and a working capital deficiency of $134,605.
The Company is actively exploring various options to address the financial difficulty issues of Potanicals, including increasing its sales from inventory, cutting its costs, restructuring its operations, and undertaking an equity or debt financing. To meet such funding requirements, if the Company closes an additional equity financing, it would be dilutive to existing shareholders. Debt financing, if available, may also involve restrictions on financing and operating activities. There is no assurance that such additional financing will be available on terms acceptable to the Company or at all. If the Company is unable to obtain additional financing as needed, it may be required to reduce the scope of the operations of Potanicals or any planned expansion. No assurances can be given that the Company will be able to raise the additional funding that may be required for such activities. The Company will provide further updates on this matter as it develops.
Benchmark is a diversified multi-licensed cannabis producer focused on a three-way vertical business model targeting the medical and recreational markets in Canada. The Company’s business plan also includes a strategy to become a Canadian licensed producer to pioneer selling medical cannabis and hemp throughout Asia, in countries where it is legal to do so.
Benchmark is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company’s global footprint.
Benchmark’s 100% owned subsidiary, Potanicals Green Growers Inc. (“Potanicals) is a Health Canada licensed producer under the Cannabis Act and its regulations. The Company is producing at its indoor Peachland, BC Cannabis Complex and is constructing a Phase II expansion of an additional 10,000 square foot extraction facility there. Along with cultivation and production, the company’s Peachland BC facility also provides propagation, cultivation, cloning, storage, research and development, genetic improvements.
As part of its expansion strategy, the company and a joint venture partner completed a second facility, a 4-acre Greenhouse Operation in Pitt Meadows, BC. The Company, through Potanicals, has received its second cultivation license, effective November 29, 2019, from Health Canada for the Pitt Meadow greenhouse.
If you would like to be added to Benchmark’s news distribution list, please sign up at Investor Relations firstname.lastname@example.org.
ON BEHALF OF THE BOARD OF
BENCHMARK BOTANICS INC.
Chief Executive Officer
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.
This news release contains forward-looking statements pertaining to various risks and uncertainties regarding future events. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Actual results could differ materially from those currently anticipated due to a number of factors and risks including the risk factors discussed in this news release and in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com and on the CSE website. These statements speak only as of the date of this news release. Except as required by law, the Company does not intend to update these forward-looking statements.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/66763
PURA Addresses Next Steps to Issue Dividend of PAOG Stock
Dallas, Texas–(Newsfile Corp. – October 23, 2020) – Puration, Inc. (OTC Pink: PURA) today announced that PURA management and PAO Group, Inc. (OTC Pink: PAOG) management have scheduled combined efforts next week to complete the joint documentation and submission requirements necessary to execute the planned dividend of PAOG stock to PURA shareholders. A joint PURA and PAOG announcement is scheduled for next Friday, October 30, 2020. The dividend update announcement comes today in conjunction with the overall corporate update scheduled for release today and included in its entirety below:
Last month, PURA introduced Farmersville Brands and announced a major juncture in the company’s growth and development as the company pivots from its hemp derived CBD beverage industry foundation to launch a Texas flavored, holistic lifestyle branded approach into a broader, but still niche, $20 billion sector within an overall market worth at least $2 trillion.
January of this year, PURA launched an acquisition campaign as a forerunner initiative to the Farmersville Brands transition.
Since launching the acquisition campaign in January, the company has acquired a CBD confections business, a CBD pet products business and CBD sun care business. Combined with its existing beverage industry product line, PURA’s combined horizontal market opportunity ranges across over $2 trillion in market value:
Central to the Farmersville Brands transition is the construction of a lifestyle brand that embodies the values, interests, attitudes, and opinions of the population where CBD and hemp products are an ideal fit.
Farmersville Brands holistic lifestyle approach will include a certain Texas personality component built on a targeted 72-acre property in Farmersville, Texas, just north of Dallas, expected to soon be acquired by PURA.
The location is intended to be a hemp mecca were visitors can participate in and learn about the reintroduction of hemp into the American market. Visitors can engage on a recreational weekend sojourn, or engage in a professional capacity to explore the best agricultural and processing practices, and new innovative methods for utilizing hemp to construct homes or to power cars.
Earlier this week, on Wednesday, PURA announced executing a contract to purchase the 72-acre farmland parcel located in Farmersville, TX, for a consideration of $1.3 million. This is a key step in the Farmersville Brand strategy transition.
PURA also has a planned $100 million investment strategy developing to fund the Farmersville transition. The company is keeping details under wraps at the moment but anticipates making the plan pubic before year end.
PAOG Dividend Next Steps
PAO Group, inc. (OTC Pink: PAOG) recently acquired a hemp cultivation business from PURA. PAOG is building a partnership with PURA in conjunction with PAOG’s new hemp cultivation business. PAOG has announced working with PURA’s new hemp processing facility in Farmersville, Texas where the two companies will partner on the construction of a greenhouse for cultivating pharmaceutical grade hemp and a lab for CBD extraction.
PAOG’s partnership includes making PURA shareholders, shareholders of PAOG. PAOG’s purchase of PURA included a PAOG stock issued to PURA shareholders in a dividend distribution. The timing of the execution of the dividend has been impacted by PAOG’s overall large volume of work surrounding the integration of its recently acquired RespRx CBD treatment for Chronic Obstructive Pulmonary Disease (COPD) and its newly acquired hemp cultivation operations. PAOG and PURA management have committed time together next week to get the dividend process over the speed bump. A joint progress announcement is planned for a week from today, next Friday, October 30, 2020.
For more information on Puration, visit http://www.purationinc.com
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/66751
PAOG Signs Clinical Research Organization (CRO) to Advance Respiratory Cannabis Treatment Through Regulatory Approval
Sandusky, Ohio–(Newsfile Corp. – October 23, 2020) – PAO Group, Inc. (OTC Pink: PAOG) today announced executing a master services agreement with a clinical research organization in the U.S. to prepare PAOG for initiating an investigational New Drug application (IND) with the Food and Drug Administration (FDA). PAOG signed the agreement yesterday, prior to the comprehensive corporate update scheduled for publication today and included in its entirety below.
Less than 90 days ago, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY) and began to transform the company into a cannabis biopharmaceutical development operation. The company has come a long way very quickly and management believes the rapid progress has been possible based on the merits of the research backing RespRx.
RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disease (COPD) derived from a patented cannabis extraction method – U.S. Patent No. 9,199,960 entitled, “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT”.
In an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated affecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis.
The CRO agreement signed yesterday is a year long agreement and a major step forward to advancing RespRx through the regulatory approval process. PAOG plans to make a joint announcement next week with the CRO company.
As previously announced, and in addition to the CRO agreement announced today, PAOG continues to develop pharmaceutical research and development relationships in Puerto Rico’s burgeoning, recently reinvigorated pharmaceutical industry. An announcement of an anticipated key contract in Puerto Rico is expected soon.
Part of PAOG’s pharmaceutical development strategy includes the development of a proprietary hemp cultivar. In addition to acquiring RespRx from KALY, PAOG recently acquired a hemp cultivation business from Puration, Inc. (OTC Pink: PURA). PAOG is building a partnership with PURA in conjunction with PAOG’s new hemp cultivation business. PAOG has announced working with PURA’s new hemp processing facility in Farmersville, Texas where the two companies will partner on the construction of a greenhouse for cultivating pharmaceutical grade hemp and a lab for CBD extraction.
PAOG’s partnership includes making PURA shareholders, shareholders of PAOG. PAOG’s purchase of PURA included a PAOG stock issued to PURA shareholders in a dividend distribution. The timing of the execution of the dividend has been impacted by the overall large volume of work surrounding the integration of the RespRx and hemp cultivation operations and the prioritization of establishing a CRO contract. PAOG and PURA management have committed time together next week to get the dividend process over the speed bump. A joint progress announcement is planned for a week from today, next Friday, October 30, 2020.
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/66743
Cannabis4 weeks ago
MustGrow Commences Banana ‘Panama Disease’ Testing in Colombia
Cannabis3 weeks ago
Bud & Tender® raise testing and quality standards for best CBD oil in the UK
Cannabis3 weeks ago
The World’s Greatest Weight Loss Secret May be Psilocybin
Cannabis4 weeks ago
MediPharm Labs Secures 100% Ownership of its Australia Subsidiary, Poised for New Wave of Global Medicinal Cannabis Growth
Cannabis2 weeks ago
Aither Ingredients Announces Joint Venture With Thar Process Intended to Disrupt the Canadian Cannabis-based Ingredient Market
Cannabis4 weeks ago
WeedMD Reports Second Quarter 2020 Financial Results and Closes $30 Million Credit Facility with LiUNA Pension Fund
Cannabis3 weeks ago
PAOG Engages Saul Kaye, Founder of iCAN: Israel-Cannabis and CannaTech to Prepare RespRx for IND
Cannabis4 weeks ago
Christina Lake Announces Commencement of Trading on the CSE